Investigational drug · Phase 3
pegargiminase
Also called: ADI-PEG 20
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
18
Any phase or sponsor naming "pegargiminase"
First trial start
2020
Sep 14, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "pegargiminase", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Glioblastoma Multiforme (GBM)
- Hepatocellular Carcinoma
- Advanced Hepatocellular Carcinoma
- Nonalcoholic Steatohepatitis (NASH)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Brain tumors (glioma) · MASH (fatty liver disease) · Oncology · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "pegargiminase" as an intervention, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaPivotal-lookingRecruiting
Polaris GroupIndustry
NCT05317819 · 300 participants (planned) · Start Mar 14, 2022 · Primary completion Sep 2028
Drug: ADI-PEG20 · For: Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma
Sites: Changhua, Taiwan; Chiayi City, Taiwan; Kaohsiung City, Taiwan · 11 sites in all
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)Pivotal-lookingTerminated
Polaris GroupIndustry
NCT05712694 · 218 participants · Start Nov 29, 2023 · Primary completion May 25, 2026
Drug: ADI PEG20 · For: Soft Tissue Sarcoma
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 30 sites in all
Polaris GroupIndustry
NCT02102022 · 140 participants · Start Nov 2014 · Primary completion Feb 2020
Drug: ADI-PEG 20 plus modified FOLFOX6 · For: Advanced Gastrointestinal (GI) Malignancies; Hepatocellular Carcinoma; Gastric Cancer and 1 more
Sites: San Francisco, California; Atlanta, Georgia; Chicago, Illinois · 35 sites in all
- Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaPivotal-lookingStatus unknown
Chang Gung Memorial HospitalAcademic, hospital or other
NCT06034977 · 120 participants (planned) · Start Dec 1, 2023 · Primary completion Jul 23, 2026
Drug: ADI-PEG20 · For: Hepatocellular Carcinoma
Sites: Taoyuan, Taiwan
Washington University School of MedicineAcademic, hospital or other
NCT03449901 · 98 participants · Start May 9, 2018 · Primary completion Jul 8, 2022
Drug: pegylated arginine deiminase; Gemcitabine and 1 more · For: Soft Tissue Sarcoma
Sites: Palo Alto, California; Santa Monica, California; St Louis, Missouri · 4 sites in all
- Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)Not yet recruiting
Sabine Mueller, MD, PhDAcademic, hospital or other
NCT07389278 · 97 participants (planned) · Start Jun 1, 2027 · Primary completion Jun 30, 2032
Drug: ADI-PEG 20 (Arginine deiminase pegylated); Temozolomide (TMZ) · For: Glioblastoma; High-Grade Glioma (WHO III-IV); High-grade Glioma and 2 more
Sites: San Francisco, California
Barts & The London NHS TrustAcademic, hospital or other
NCT01279967 · 70 participants · Start Jan 2011 · Primary completion Jan 2015
Drug: ADI-PEG 20 · For: Malignant Pleural Mesothelioma
Sites: Brighton, United Kingdom; Cambridge, United Kingdom; Hull, United Kingdom · 7 sites in all
Polaris GroupIndustry
NCT05842512 · 60 participants (planned) · Start Sep 13, 2023 · Primary completion Dec 31, 2027
Drug: ADI-PEG20 · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Chiayi City, Taiwan; Kaohsiung, Taiwan; Keelung, Taiwan · 10 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07702162 · 49 participants (planned) · Start Nov 14, 2025 · Primary completion Feb 2, 2027
Drug: PA5 · For: Advanced Solid Tumors; Cancer
Sites: Fuzhou, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in the treatment of pleural mesothelioma.
Jakopovik M, Ljubičik L, Bitar L · Curr Opin Oncol 2026
- The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report.
Yu J, Lin YH, Yeh CT, et al. · In Vivo 2026
- Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma.
Pavlyk I, Field G, Young M, et al. · Pigment Cell Melanoma Res 2026
- Dysregulation of the urea cycle - potential targets for treatment and diagnosis in prostate cancer.
Ladurner M, Klocker H, Neuwirt H, et al. · Expert Rev Mol Med 2026
- Loss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase.
Knipper K, Lyu SI, Tzitzili E, et al. · Cancers (Basel) 2025
- Arginine deiminase-polymeric hybrid nanoconjugates: A potential biodrug for targeted treatment of arginine auxotrophic cancers.
Kawatra A, Gulati P · Int J Biol Macromol 2025
Also in development for Glioblastoma Multiforme (GBM)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- JK-1201IPhase 32 trials
JenKem Technology Co., Ltd. · Glioblastoma Multiforme (GBM), Small Cell Lung Cancer
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.